Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva santé animale - genetski modificirani рекомбинантный Шига-toksin-antigen 2e - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - svinje - aktivna imunizacija praščića od dobi od četiri dana, kako bi se smanjila smrtnost i klinički znakovi bolesti edema uzrokovanih shiga toksinom 2e koji su proizveli escherichia coli (stec). početak imuniteta: 21 dan nakon cijepljenja. trajanje imuniteta: 105 dana nakon cijepljenja.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastična sredstva - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

molmed spa - alogenih t stanica genetski modificirani sa retrovirusni vektor kodiranje za skraćeni oblik ljudske nizak afinitet receptora faktora rasta živaca (Δlngfr) i herpes simplex virus timidin kinaze (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastična sredstva - zalmoksis je indiciran kao dodatna terapija u haploidentical hematopoetskih matičnih stanica (hsct) odraslih bolesnika s visokog rizika hematoloških malignih bolesti.

Europska Unija - hrvatski - EMA (European Medicines Agency)

rhythm pharmaceuticals netherlands b.v. - setmelanotide - gojaznost - pripravci protiv pretilosti, isključujući. prehrambeni proizvodi - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Europska Unija - hrvatski - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - drugi gastrointestinalni trakt i metabolizam, lijekovi, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolizam aminokiselina, urođene pogreške - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastični agensi - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantel-stanica - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multipli mijelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.